Latest news newssearch boxGO 01 Apr 2021 Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders 26 Mar 2021 The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis 19 Mar 2021 US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis 10 Mar 2021 FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia 03 Mar 2021 Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia 01 Mar 2021 Idorsia submits NDA for clazosentan to Japanese PMDA 04 Feb 2021 Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data 02 Feb 2021 Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal 11 Jan 2021 Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA 23 Nov 2020 Idorsia announces positive results of the two Japanese registration studies with clazosentan 27 Oct 2020 Idorsia announces financial results for the first nine months of 2020 21 Oct 2020 Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million 20 Oct 2020 Idorsia announces the results of its rights offering in the context of the capital increase 08 Oct 2020 Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline 02 Sep 2020 Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting 02 Sep 2020 Idorsia assigns and transfers agreement with ReveraGen to Santhera 31 Aug 2020 Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States 28 Aug 2020 Daridorexant Phase 3 results in insomnia presented at SLEEP 2020 13 Aug 2020 Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020 06 Aug 2020 Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing 1 2 3 4
